These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23474756)

  • 41. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
    Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.
    Wang X; Studzinski GP
    J Cell Physiol; 2011 May; 226(5):1232-40. PubMed ID: 20945381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and regulation of receptor tyrosine kinases Rse and Mer and their ligand Gas6 in testicular somatic cells.
    Chan MC; Mather JP; McCray G; Lee WM
    J Androl; 2000; 21(2):291-302. PubMed ID: 10714824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner.
    Fraineau S; Monvoisin A; Clarhaut J; Talbot J; Simonneau C; Kanthou C; Kanse SM; Philippe M; Benzakour O
    Blood; 2012 Dec; 120(25):5073-83. PubMed ID: 23065156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
    Graham DK; Salzberg DB; Kurtzberg J; Sather S; Matsushima GK; Keating AK; Liang X; Lovell MA; Williams SA; Dawson TL; Schell MJ; Anwar AA; Snodgrass HR; Earp HS
    Clin Cancer Res; 2006 May; 12(9):2662-9. PubMed ID: 16675557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells.
    Wu Y; Singh S; Georgescu MM; Birge RB
    J Cell Sci; 2005 Feb; 118(Pt 3):539-53. PubMed ID: 15673687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
    Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL; Sather S; Zhang D; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
    J Med Chem; 2014 Aug; 57(16):7031-41. PubMed ID: 25068800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation.
    Guttridge KL; Luft JC; Dawson TL; Kozlowska E; Mahajan NP; Varnum B; Earp HS
    J Biol Chem; 2002 Jul; 277(27):24057-66. PubMed ID: 11929866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
    Voutsadakis IA
    Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.
    Zhang W; Konopleva M; Burks JK; Dywer KC; Schober WD; Yang JY; McQueen TJ; Hung MC; Andreeff M
    Cancer Res; 2010 Mar; 70(6):2424-34. PubMed ID: 20215498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.
    Brobeil A; Bobrich M; Graf M; Kruchten A; Blau W; Rummel M; Oeschger S; Steger K; Wimmer M
    Leuk Res; 2011 Oct; 35(10):1367-75. PubMed ID: 21513978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.
    Migdall-Wilson J; Bates C; Schlegel J; Brandão L; Linger RM; DeRyckere D; Graham DK
    PLoS One; 2012; 7(2):e31635. PubMed ID: 22363695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
    Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan AC; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ; Eckhardt SG; Kuan PF; Hamilton RL; Duncan LM; Miller CR; Nikolaishvili-Feinberg N; Midkiff BR; Liu J; Zhang W; Yang C; Wang X; Frye SV; Earp HS; Shields JM; Graham DK
    J Clin Invest; 2013 May; 123(5):2257-67. PubMed ID: 23585477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
    Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.